Tick-borne Encephalitis Vaccine

Tick-borne encephalitis vaccine is a vaccine used to prevent tick-borne encephalitis, a disease most common in Central and Eastern Europe and Northern Asia, with more than 87 percent of recipients developing immunity, though the vaccine is not useful after the bite of an already-infected tick. The World Health Organization recommends immunizing all people in areas where the disease is common, with three doses followed by additional booster doses every three to five years, and the vaccine appears to be safe during pregnancy. The first vaccine against tick-borne encephalitis was developed in 1937, and it was approved for medical use in the United States in August 2021; it is on the World Health Organization's List of Essential Medicines.